Stocksigma LogoStocksigma Logo

CORONA Remedies Reports Strong H1 FY27 Performance Driven by Chronic Segment Outperformance

CORONA Remedies reported revenue of INR 863.6 Cr (+22.0% YoY), EBITDA of INR 189.1 Cr (+27.5% YoY, margin 21.9%), and PAT of INR 120.4 Cr (+22.2% YoY) for

CORONA Remedies Reports Strong H1 FY27 Performance Driven by Chronic Segment Outperformance

Corona Remedies Ltd 路 Investor Presentation 路 31 Oct 2026, 2:13 am

CORONA Remedies Reports Strong H1 FY27 Performance Driven by Chronic Segment Outperformance CORONA Remedies reported revenue of INR 863.6 Cr (+22.0% YoY), EBITDA of INR 189.1 Cr (+27.5% YoY, margin 21.9%), and PAT of INR 120.4 Cr (+22.2% YoY) for H1 FY27, with annualized ROCE at 49.8% and ROE at 32.9%. Q2 FY27 revenue grew 22.2% YoY to INR 441.2 Cr. Chronic and sub-chronic therapies contributed ~72.1% of H1 FY27 revenue, while India accounted for 97.1%. The company secured ANVISA GMP certification for its Bhayla OSD and hormone facility in Oct'26.

Original exchange filing (PDF)

More announcements from Corona Remedies Ltd

All Corona Remedies Ltd announcements